Print version ISSN 0037-8682
Rev. Soc. Bras. Med. Trop. vol.45 no.4 Uberaba July/Aug. 2012
Avaliação comparativa de efeitos adversos no uso do soro antiofídico trivalente liofilizado e soros antiofídicos líquidos no acidente botrópico
Iran Mendonça da SilvaI,II; Antônio Magela TavaresIII
IInstituto de Biologia do Exército, Rio de Janeiro, RJ
IIFaculdade de Medicina, Universidade Estadual do Amazonas, Manaus, AM
IIIDepartamento Clínico, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, AM
INTRODUCTION: Snake bite, a problem in public health, generally occurs where there is no electric power.
METHODS: A comparative clinical study was conducted with 102 victims of Bothrops snake bite, from the state of Amazonas, Brazil; 58 victims were treated with liofilizated trivalent antivenom serum (SATL) and 44 victims treated with liquid bivalent and monovalent antivenom serum (SAMBL).
RESULTS: 17% (10/58) of patients presented adverse effects with the SATL and 25% (11/44) with the SAMBL.
CONCLUSIONS: There was no statistic difference in number of adverse effects between the two types of snake bite antivenom.
Keywords: Bothrops. Antivenoms. Adverse effects.
INTRODUÇÃO: Acidente ofídico, problema de Saúde Pública, é mais frequente onde não há energia elétrica.
MÉTODOS: Foi realizado estudo clínico comparativo com 102 vítimas de acidente botrópico, do Estado do Amazonas, Brasil; 58 vítimas tratadas com soro antiofídico trivalente liofilizado (SATL) e 44 vítimas tratadas com soro antiofídico monovalente e bivalente líquido (SAMBL).
RESULTADOS: A comparação entre os tipos de soro demonstrou 17% (10/58) de indivíduos com eventos adversos com o uso de SATL e 25% (11/44) com o uso dos SAMBL.
CONCLUSÕES: Não houve diferença estatística na quantidade de reações adversas entre os dois tipos de soros antiofídicos.
Palavras-chaves: Bothrops. Soro antiofídico. Efeitos adversos.
In Brazil, snake bite is a problem in public health1; generally, it occurs where there is no electric power, far from hospitals, for example, in forests of the Amazon Region, in field activities, and in communities of people of indigenous origin2-4, where this study was conducted. The registers of the Brazilian Health Ministry list about 20,000 victims of snake bite per year in the Brazilian territory. This statistic number is not exact, as many snake bites occur where there is no health unit to handle the notification. Many times, the victims allow the snake bites to naturally heal without antivenoms and in some cases with significant complications5-7. They lose fingers, legs, hands, and arms, and they cannot work as well as they could before the snake bite. They have serious complications such as infections, kidney failure and death8. In these distant regions, because of the lack of electric power, it is impossible to conserve the liquid antivenom in low temperature between 20C and 80C, as recommended.
This evaluation is a clinical study to verify the safety of the Brazilian powder trivalent antivenom compared with the Brazilian liquid antivenom, made by the Butantan Institute, in the state of São Paulo, Brazil and the Ezequiel Dias Foundation (Fundação Ezequiel Dias - FUNED) and Vital Brazil Institute (Instituto Vital Brasil - IVB). The powder trivalent antivenom was also made in the Butantan Institute in association with the Biological Institute of Brazilian Army, in Rio de Janeiro (Instituto de Biologia do Exército - IBEx). Thus, Butantan Institute handled the final industrial production and the IBEx performed the clinical study.
The SATL was produced by the Butantan Institute in association with the IBEx. A prospective study was realized to compare the adverse effects between two antivenoms. During the 6 years of comparative study, the powder antivenom was revalidated after analysis and emission of the Butantan Institute certification to perform the analysis without interruption. To be considered for inclusion in the project, the patients had to have only light to moderate snake bite damages. We considered that during this phase, the severe envenoming could be a variable to confuse the results. The participants in the study should not be pregnant and had to be between 12 and 70 years of age; this selection of age was to avoid the exclusion of victims in rural work5 and to exclude immunological vulnerability and others diseases commonly found outside this range (i.e., those previous snake bite treatments and who are free from allergic effects caused by horsehairs and other horse proteins). In the case of the victims of the Bothrops snake bite, the participants to be treated with liquid or powered antivenom were chosen randomly after diagnosis of envenoming, after explanation about the project and after signing the informed consent form. The clinical experiment was considered a simple blind study, that is, only the health workers knew which antivenom was being used. The patients were not informed; they knew only that they were participating in a project comparing two kinds of antivenom. The protocol of this study was approved by the Research Ethics Committee of the Army Biology Institute (Instituto de Biologia do Exército), Rio de Janeiro, and it was sent to National Ethical Committee. The guidelines for human experimentation of the National Health Council were followed in the conduct of clinical research. The Pearsons χ2 test was used to statistic analysis of results9. The patients were treated in Dr. Heitor Vieira Dourado - Tropical Medicine Foundation (Fundação de Medicina Tropical Dr. Heitor Vieira Dourado - FMT-HVD).
After the use of antagonists of alpha-1 and alpha-2 receptors (cimetidine 300mg IV and dexchlorpheniramine 10ml oral route and hydrocortisone 500mg IV), according to snake bite degree (e.g., light snake bite = two flasks of SATL or four to six ampoules of SAMBL; moderate snake bite = four flasks of SATL or eight to twelve ampoules of SAMBL), the antivenom injection was done under medical supervision to permit the detection of adverse effects, in accordance to the objective of this study. The snake bite victims were hospitalized for a period of 24h or more. After this, if there were no complications to justify further confinement in the hospital, the victim was sent home with instructions to return on the seventh day and after the fifteenth day after the snake bite. On those occasions, they were evaluated for delayed adverse effects. The quantitative and qualitative registers of detected effects were presented by graphs of comparative analysis between the SATL and the SAMBL (Figure 1).
The distribution of snake bite victims according by characteristic of antivenom was 57% (58/102) to SATL and 43% (44/102) to SAMBL, the ratio of patients were equals (0.5) to both groups of patients, SATL (p-value=0.09, CI=95%) and SAMBL (p-value=0.9, CI=95%).
When the adverse effects between the antivenoms are compared, there are 17% (n=58) of persons with adverse effects with the SATL and 25% (n=44) with the SAMBL (p-value=0.47, CI=99%), the ratio of adverse effects is equal to both in statistic analysis. Although the total number of evaluated victims is only 102 persons, it is possible to say that to this moment (Project Phase II) and in these cases, that the SATL is as safe as SAMBL because had no statistic difference in number of adverse effects between the two antivenoms, as described in Figure 2 . The more frequent adverse effects with the SATL were urticaria, pruritus, facial rubor and vomiting; with the SAMBL the more frequent adverse effects were pruritus, urticaria, vomiting and headache (Figure 1). In according of literature10-12, the adverse effects presented in this study were expected to occur and could be controlled with other medicines, as soon as they appeared. It was not reason to stop the treatment with both antivenoms (SATL and SAMBL). To urticaria it was 31.3% with SATL and 30.8% with SAMBL (p-value=1), to pruritus it was 25% with SATL and 38.5% with SAMBL (p-value=0.58) and to others adverse effects it was 43.8% to SATL and 30.8% to SAMBL (p-value=0.63), there was no statistic significance between the two, although there was good tolerance to both antivenoms (Figure 2).
There were no more adverse effects in the SATL, which was made with three different immunoglobulins, in agreement with the experiences in India13. We believed that this antivenom can be used when the genus of snake is not known. In the economic aspect, it is clear that the SATL is better than the SAMBL, as it could be used until eight years, eleven months and seven days after fabrication, after revalidation of the study. The SATL was safe for the Bothrops snake bite. The epidemiological, clinical and therapeutic aspects were studied, and the SATL is viable with priority to the regions where access is difficult due to the long distances from the public health unit. Every patient who used the SATL went home without complications and as evaluated until 15 days after the specific therapy. There was no difference in the safety between both antivenoms (SATL and SAMBL). It is necessary to make the SATL in Brazil because it is more economic for the government and is better to the people living long distances from the public health unit. The SATL was used for almost nine years after its production and the SAMBL used until three years after the efficacy was determined.
The principal objective is to the Amazon Region, where there are important epidemiological characteristics, such as when the public health unit is far from the primary forest and agriculture regions, when there is no electric power to conserve the liquid antivenom in cold temperatures (20C to 80C), and because there are the three genera of snakes (Chrotalus, Bothrops and Lachesis) in the Amazon Region and sometimes it is difficult to distinguish the snake after the bite.
CONFLICT OF INTEREST
The authors declare that there is no conflict of interest.
Instituto de Biologia do Exército, Rio de Janeiro, RJ.
1. Rodrigues DS, Teles AMS, Machado MAML, Vargens MML, Nascimento IM, Planzo TMP. Ofidismo na Bahia: Um problema de Saúde Pública. Rev Soc Bras Tox 1988; 23-26. [ Links ]
2. Borges CC, Sadahiro M, Santos MC. Aspectos epidemiológicos e clínicos dos acidentes ofídicos ocorridos nos municípios do Estado do Amazonas. Rev Soc Bras Med Trop 1999; 32:637-646. [ Links ]
3. Feitosa RFG, Melo IMLA, Monteiro HSA. Epidemiologia dos acidentes por serpentes peçonhentas no estado do Ceará Brasil. Rev Soc Bras Med Trop 1997; 30:295-301. [ Links ]
4. Pardal PPO, Rezende MB, Dourado HV. Acidentes Ofídicos. In: Queiroz-de-Leão RN, editor. Doenças Infecciosas e Parasitárias: Enfoque Amazônico. Belém: Editora CEJUP; 1997; 805-811. [ Links ]
5. Ribeiro LA, Albuquerque MJ, Pires-de-Campo VAF, Katz G, Takaoka NY, Lebrão ML, et al. Óbitos por serpentes peçonhentas no Estado de São Paulo: Avaliação de 43 casos, 1988/93. Rev Ass Med Bras 1998; 44:312-318. [ Links ]
6. Vêncio D. Estudo do ofidismo em Goiás: Comprometimento da função renal. Rev Goiana Med 1988; 34:95-116. [ Links ]
7. França FOS, Málaque CMS. Acidente Botrópico. In: Cardoso JLC, França FOS, Wen FH, Malaque CMS, Haddad Jr, editor. Animais Peçonhentos no Brasil Biologia, Clínica e Terapêutica dos Acidentes. São Paulo: Editora Savier 2003; p.72-86. [ Links ]
8. Nascimento SP, Noronha MD, Muniz EG, Lópes-Lozano JL, Alves-Gomes JÁ. Características Epidemiológicas e Clínicas dos Acidentes por Serpentes Peçonhentas no Estado de Roraima, Brasil. Mens Agitat 2007; 1. [ Links ]
9. Chen D, Peace KE. Clinical Trial Data Analysis Using R Chapman & Hall/CRC Biostatistics Series 2011; 52. [ Links ]
10. Moreno E, Queiroz-Andrade M, Lira-da-Silva, Tavares-Neto J. Características clínicoepidemiológicas dos acidentes ofídicos em Rio Branco, Acre. Rev Soc Bras Med Trop 2005; 38:15-21. [ Links ]
11. Ribeiro LA, Jorge MT. Acidente por serpentes do gênero Bothrops: série de 3.139 casos. Rev Soc Bras Med Trop 1997; 30:475-480. [ Links ]
12. Ribeiro LA, Jorge MT. Alteração do tempo de coagulação sangüínea em pacientes picados por serpente Bothrops jararaca adulta e filhote. Rev Hosp Clin Fac Med São Paulo 1989; 44:1143-1145. [ Links ]
13. Mahadevan S. Anti snake antivenom (ASV) reactions - a perspective. Drug Alert - Regional Pharmacovigilance Center (South) - Department of Pharmacology, JIPMER, Pondicherry - India 2005; I:1-2. [ Links ]
Dr. Iran Mendonça da Silva
Travessa Laguna 12. Lírio do Vale
69038-010 Manaus, AM, Brasil
Phone: 55 92 2127-3496; Fax: 55 92 2127-3462
Received in 07/12/2010
Accepted in 19/09/2011